Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 16/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807516 | 0.81 | PI4KA (0.41) | DHFRTLR8TLR7PI4KAPI4K2B | |
| SCHEMBL9036182 | 0.69 | TLR7 (0.52) | TLR8TLR7 | |
| SCHEMBL20134736 | 0.68 | DHFR (0.67) | DHFR | |
| SCHEMBL16984491 | 0.67 | DHFR (0.70) | DHFR | |
| SCHEMBL5509023 | 0.67 | KDM4E (0.36) | DHFRTLR8TLR7 | |
| SCHEMBL18109747 | 0.67 | DHFR (0.69) | DHFR | |
| SCHEMBL9038851 | 0.64 | PARP1 (0.57) | TLR8TLR7 | |
| SCHEMBL18587589 | 0.64 | TLR8 (0.48) | TLR8TLR7 | |
| SCHEMBL20968317 | 0.64 | PARP1 (0.41) | TLR8TLR7 | |
| SCHEMBL23422173 | 0.63 | TLR8 (0.37) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673932-B2 | Oxime substituted imidazo-containing compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066639-A1 | Oxime substituted imidazoquinolines | IFNG, IRF3, IL2 | DHFR 244/4885TLR8 139/4885TLR7 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.